HER2-low metastatic breast cancer: molecular insights and therapeutic strategies  

在线阅读下载全文

作  者:Francisco J.Esteva Shabnam Jaffer 

机构地区:[1]Division of Hematology and Medical Oncology,Lenox Hill Hospital,New York,NY 10065,USA [2]Department of Pathology,Lenox Hill Hospital,New York,NY 10065,USA

出  处:《Journal of Cancer Metastasis and Treatment》2023年第1期541-547,共7页癌症转移与治疗(英文版)

摘  要:The identification of HER2-low metastatic breast cancer as a novel subgroup with therapeutic implications underscores the intricacies in breast cancer classification.This subset,comprising 45%-60%of breast cancer cases,presents a challenge due to its heterogeneous nature,characterized by varying HER2 protein expression levels.This heterogeneity complicates diagnosis and treatment decisions.The advent of trastuzumab deruxtecan(T-DXd),a second-generation antibody-drug conjugate(ADC),instills renewed hope for HER2-low breast cancer patients,having demonstrated effectiveness in clinical trials.The article also explores the evolution of HER2 testing guidelines,notably the 2023 ASCO/CAP guidelines that acknowledge the potential benefits of HER2-targeted therapies for this subgroup.In summary,this article emphasizes the significance of collaborative efforts between Pathologists and Oncologists in the era of precision medicine.It also highlights the potential for innovative,tailored therapies for HER2-low breast cancer,promising enhanced treatment outcomes and a broader range of therapeutic options.

关 键 词:HER2-low breast cancer HETEROGENEITY trastuzumab deruxtecan(T-DXd) HER2 testing guidelines precision medicine therapeutic strategies IMMUNOHISTOCHEMISTRY in situ hybridization 

分 类 号:R73-37[医药卫生—肿瘤]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象